| |
NEW TO GROWTHWIRE? Growthwire is an investment and corporate venturing intelligence service meeting the unique needs of growth and alternative fund managers, CEOs and other business leaders. |
| Headline |
Breakthrough radioisotope manufacturing technology |
| Investment Stage |
Mezzanine
Private Placement |
| Sectors |
Science/Tech R&D - Materials
Science/Tech R&D - Bio-Tech
Health & Safety - Research & Development
Pharmaceuticals - Research & Development |
| Deal Value |
12,000,000 |
| Currency |
USA - US$ |
| Country/Region |
North America USA California |
| Summary |
The cllient has developed disruptive breakthrough accelerator technology for the production of radioisotopes used in nuclear medicine (diagnosis and therapy), industry, and national security. The clients' nuclear medical systems are small enough to reside within the radiopharmacy of the treatment facility and are able to produce 95% of currently used radioisotopes at a fraction of current costs with no quality degradation. In addition, promising highly-effective cancer treatments proven in research, but not available today in commercial quantities or at affordable prices, can be produced with this technology.
Radiopharmaceuticals sales are expected to exceed US$5 billion annually by 2015 (The Journal of Nuclear Medicine, April, 2009). The overall isotope market is many times that size, approaching approximately US$20 billion.
Aside from the many other benefits derived from this product it eliminates the large amounts of nuclear waste generated by current production methods and removes any issues with the proliferation of highly enriched uranium. The technology is highly dependable and subject to minimal downtime.
$12m required to bring the product to market. QUOTE REF 1001
To see how Growthwire works please click here.
|
|
|
PLEASE NOTE:
- INVESTORS are required to comply with the financial and money laundering regulations of the country in which the Growthwire Authorised Advisor posting this listing is domiciled.
- MEDIA. If used as a news item this alert must be acknowledged as being sourced from 'Growthwire'
|
|
|
Back
|
|
